No risk adjustment or risk stratification

Percentage of patients who were evaluated during at least one office visit for the frequency (numeric) of daytime and nocturnal asthma symptoms

Percentage of patients with asthma who have greater than or equal to one visit to the emergency room for asthma during the measurement period.

Admissions for a principal diagnosis of asthma per 100,000 population, ages 18 to 39 years. Excludes admissions with an indication of cystic fibrosis or anomalies of the respiratory system, obstetric admissions, and transfers from other institutions.

The percentage of patients 5–64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.

Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication

Three rates are reported for this measure:
1. Patients prescribed inhaled corticosteroids (ICS) as their long term control medication
2. Patients prescribed other alternative long term control medications (non-ICS)
3. Total patients prescribed long-term control medication

Percentage of patients, age >=18 and <= 120 at diagnosis, who have their first diagnosis of cancer (epithelial malignancy), whose primary tumor is of the colon, and had at least 12 regional lymph nodes removed and pathologically examined for resected colon cancer

The percentage of patients aged 12 years and older with coronary artery disease, or 18 years and older with cerebrovascular disease or peripheral vascular disease that have been screened for dyslipidemia with a lipid profile

The percentage of patients aged 18 and older with a diagnosis of atherosclerotic disease whose most recent LDL-C value is greater than 100 mg/dL and who are taking a lipid lowering agent

Percentage of adult patients aged 25 and older with atrial fibrillation and major stroke risk factors who are on anticoagulation therapy.

Percentage of patients aged 18 years and older with a diagnosis of nonvalvular atrial fibrillation (AF) or atrial flutter whose assessment of the specified thromboembolic risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS2 risk stratification, who are prescribed warfarin OR another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism